Louis Garguilo

ARTICLES BY LOUIS

  • Magenta Therapeutics Finds A “Support Chain” Beyond CDMOs
    Magenta Therapeutics Finds A “Support Chain” Beyond CDMOs

    Biotechs focused on cell and gene therapies need support beyond the traditional outsourcing of development and manufacturing to CDMOs. These elongated “support chains” start within the healthcare system, run cells out to a CDMO for processing, and then circle back to the patient. Jason Gardner, co-founder, CEO and president of Magenta Therapeutics, believes he’s found a partner to help.

  • Bigger Pharma Supports Biotech Outsourcing
    Bigger Pharma Supports Biotech Outsourcing

    Mersana Therapeutics has a powerful weapon in its battle to combat supply-chain complexity: A collaborative partnership with Takeda’s Millennium. We’ll look at how Takeda assists this biotech in the contract development and manufacturing of drug candidates. Today more than ever, biotechs rely on this type of Bigger Pharma assistance. 

  • You Can Do Everything Right, But Still Get Burned By Outsourcing
    You Can Do Everything Right, But Still Get Burned By Outsourcing

    This is a narrative of how a virtual biotech did everything in its power to execute on an outsourcing strategy, but still suffered a critical setback at its service provider, told be Marilyn Bruno, CEO of Aequor, Inc. 

  • Lessons From Mersana’s Outsourced Model For ADCs
    Lessons From Mersana’s Outsourced Model For ADCs

    Antibody-drug conjugates (ADCs) are on the move in the regulatory approval pipeline. Time again for us to view this technology through our prism of external support systems to see what we can further learn about our industry. Luckily, we get that view through the eyes of Michael Kaufman, Senior Vice President of CMC for Cambridge, Mass-based Mersana Therapeutics

  • Two Strategies For Getting Your CMO To Really Listen
    Two Strategies For Getting Your CMO To Really Listen

    “When you select a vendor and agree to a contract, your roles are now somewhat reversed. You were the boss before you handed out the contract, but the minute the contract is done, you lose the leverage you had. How can you maintain more control?” Here are two strategies from biotech and pharma executives.

  • Outsourcing Dreams In Latin America
    Outsourcing Dreams In Latin America

    When Boehringer Ingelheim swapped its consumer healthcare assets with Sanofi, Edgardo Rodriguez went along, too. It was like walking to the other side of the street in his beloved Buenos Aires. And his “new” job at Sanofi runs down the same road: Manage a supply chain for a European pharmaceutical company that includes dozens of CDMOs throughout Latin America. 

  • Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing
    Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing

    Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”

  • Comfortable CMO Consolidation And Biopharma Convergence
    Comfortable CMO Consolidation And Biopharma Convergence

    The biopharma industry has been calling for more consolidation and convergence in the CRO, CDMO and CMO market. Well, we are now getting our share of it. And it is bringing on some creative deal-making, and unexpected developments. But we seem comfortable with what is transpiring. Here’s why.

  • How To Get Saved By A Drug Supply Chain
    How To Get Saved By A Drug Supply Chain

    "We’re there to help service providers continue to be healthy, viable businesses,” says Phil RobertsSenior Vice President, Technical Operations, Orexigen. “I’m open to the concept that a static CDMO, is really a dead CDMO,” he concludes. But for Orexigen and its supply chain, it’s been much more of a mutually assured existence. Here’s part two of the journey. 

  • Every Company Tells A Story: Orexigen, Anti-Obesity And Outsourcing
    Every Company Tells A Story: Orexigen, Anti-Obesity And Outsourcing

    Just like with pictures, every company tells a story. For its true grit and determination in the face of regulatory and market adversity, and its survival due to the ability to quickly establish a commercial supply chain and work with outsourcing partners, no company tells us a better story than Orexigen.

Louis Garguilo

Louis Garguilo



Louis Garguilo is chief editor and conference chair for Outsourced Pharma, and a contributing editor to Life Science Leader magazine. He studied public relations and journalism at Syracuse University (and holds a Master’s in English), and has 30+ years of international experience in business communications and development positions. Louis spent a decade at a global pharmaceutical contract research, development and manufacturing organization; served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; was chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and business communications consultant, including for the Osaka Medical Center for Cancer and Cardiovascular Diseases.